WO2026002191 - NOVEL DRUG CONJUGATE AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/002191
Publication Date
02.01.2026
International Application No.
PCT/CN2025/104330
International Filing Date
27.06.2025
Title **
[English]
NOVEL DRUG CONJUGATE AND USE THEREOF
[French]
NOUVEAU CONJUGUÉ DE MÉDICAMENT ET SON UTILISATION
[Chinese]
新型药物偶联物及其用途
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
TANG, Weijia
ZHOU, Xin
LI, Shuoxu
MEI, Xingxing
YANG, Shaowei
YU, Jin-Chen
LI, Shengfeng
Priority Data
202410865146.6
29.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2421 | |
| EPO | Filing, Examination, Granting | 20227 | |
| Japan | Filing, Examination, Granting | 2616 | |
| South Korea | Filing, Examination, Granting | 3133 | |
| USA | Filing, Examination, Granting | 11540 |
Total:
39,937
Contact Us
Abstract[English]
Disclosed are a drug conjugate, such as an antibody-drug conjugate, and use thereof. The present invention pertains to the field of biopharmaceuticals. In some embodiments, the drug conjugate is a compound of formula I or a pharmaceutically acceptable salt or solvate thereof. The drug conjugate can be used for treating diseases such as cancer, autoimmune diseases, inflammatory diseases, or infectious diseases.[French]
L'invention concerne un conjugué de médicament, tel qu'un conjugué anticorps-médicament, et son utilisation. La présente invention se rapporte au domaine des produits biopharmaceutiques. Dans certains modes de réalisation, le conjugué de médicament est un composé de formule I ou un sel ou solvate pharmaceutiquement acceptable de celui-ci. Le conjugué de médicament peut être utilisé pour traiter des maladies telles que le cancer, des maladies auto-immunes, des maladies inflammatoires ou des maladies infectieuses.[Chinese]
本发明公开了药物偶联物如抗体药物偶联物及其用途，属于生物医药领域。在一些实施方案中，所述药物偶联物为式I的化合物或者其药学上可接受的盐或溶剂合物，所述药物偶联物可用于治疗疾病，如癌症、自身免疫性疾病、炎症性疾病或传染性疾病。